OVARIAN CANCER RESEARCH FOUNDATION

OCRF RESEARCH GRANT GUIDELINES

SUPPORTING INFORMATION FOR RESEARCHERS APPLYING TO THE OCRF NATIONAL RESEARCH GRANTS PROGRAM

ACN 130 949 834
www.ocrf.com.au
2/59 Keele St, Collingwood
VIC 3066

Contents

1 Ovarian Cancer Research Foundation Overview

Our Vision

A healthy vital future for all those impacted by ovarian cancer.

Our Purpose

We exist to drive step-change in funds raised, awareness, and research undertaken, for the most lethal women's cancer in Australia.

Our Values

Integrity | Ambition | Collaboration | Accountability | Heart

1.1 About the OCRF

The Ovarian Cancer Research Foundation (OCRF) is Australia's leading independent funder of ovarian cancer research, dedicated to transforming outcomes for the most lethal women's cancer. In Australia, fewer than 50 per cent of women and girls diagnosed with ovarian cancer will survive more than five years - a figure unchanged for decades, highlighting disparities and gender inequity in research and care that demand urgent action.

The OCRF is rewriting this story. Our vision is a future where those impacted by ovarian cancer can live healthy, vital lives. To achieve this, we are catalysing change and accelerating progress by increasing awareness, advocating for greater investment and equity, collaborating nationally and internationally, and strategically funding high impact medical research.

Every dollar we raise comes from the Australian community, driven by a shared determination to make our vision a reality. Together, we will overcome ovarian cancer.

1.2 OCRF'S National Research Grants Program

The OCRF funds research aligned with at least one of our research objectives, as determined in consultation with ovarian cancer researchers, clinicians, and consumers in 2024. Pursuing these objectives, proposals should aim to improve the length and quality of life of those affected by ovarian cancer as the ultimate aim.

2 OCRF Research Objectives

The OCRF's investment in medical research is guided by three key objectives; ultimately improving outcomes for people with ovarian cancer to:

i. TREAT
   Advancing treatment strategies that improve survival and quality of life, while also addressing the challenge of recurrent disease. This may include, but is not limited to, exploration of novel targets, drug screening and repurposing, investigation of combination therapies, improved understanding of

disease biology to inform therapeutic development, and exploring strategies to prevent, delay, or better manage recurrence.

ii. DETECT
Discovery and validation of accurate, reliable, non-invasive, and equitable methods for the early detection and screening of ovarian cancer to enable diagnosis at the earliest and most treatable stage.

iii. PREVENT
Advancing knowledge to uncover the biological mechanisms that drive ovarian cancer risk and initiation, with the goal of informing prevention strategies such as targeted risk reduction and prophylactic interventions.

3 Our Guiding Research Principles

Principle 1: Sustained research investment that develops the ovarian cancer research field

Sustained funding of ovarian cancer research projects has brought positive scientific outcomes and facilitated the development of passionate research teams who can progress in their field. OCRF offers multi-year grants up to three years in length, to provide stability and clarity for project teams and to attract the most innovative and skilled researchers into the field.

It encourages established leaders in the field to support mid-career researchers to submit proposals as Lead Chief Investigators, and to support early career and post-doctoral researchers in their research efforts by including them as personnel in applications. The OCRF is also intent on bringing together researchers in the field, encouraging ongoing multi-institutional and multi-disciplinary collaboration across all states in Australia and New Zealand.

Principle 2: Focus on innovation and translation

The OCRF aims to fund innovative research projects and ideas. Proposals may challenge existing paradigms and/or build upon previous relevant research which is progressing into promising territory. Where appropriate, projects should also **deploy or leverage innovative tools or technologies** to address hypotheses and drive progress in ovarian cancer research.

The OCRF will consider preliminary studies aimed at providing pilot or proof-of-concept data, with the goal of translating these findings into clinical practice. All project proposals must clearly articulate a path leading to translation of the research findings into impactful results for those who are, or may be, affected by ovarian cancer.

Principle 3: Transparency and accountability

The OCRF relies solely on the financial support of the Australian community for its grant-making activities. It is critical that the OCRF can demonstrate that funds raised by and with the Australian community is rewarded with insights from research projects funded by the OCRF.

Further, our community expects a rigorous standard of accountability in grant-making and review, along with confidence that projects we fund are well-managed, fully transparent, ethical, and impactful. Therefore, the

OCRF seeks sound financial management and responsible management of research projects to be applied throughout the duration of the project. In addition, an expectation of engagement with the OCRF is involvement in regular knowledge translation activity and reporting.

4 Grants Process Overview

The OCRF has recently implemented a two-stage grant application process, involving an Expression of Interest (EOI) stage followed by a full application stage. Developed in consultation with researchers, assessors, and partner organisations, the process is summarised below:

i. **Expression of Interest (EOI):** Researchers are invited to submit a brief EOI outlining the proposed project's aims, significance, methodology, and indicative budget. EOIs are assessed by the International Scientific Advisory Committee (ISAC) and the Consumer Review Panel (CRP).

ii. **Invitation to Full Application:** Applicants whose EOIs are deemed competitive will be invited to submit a full application. Progression to this stage is dependent on the availability of funding and the quality of EOIs received.

iii. **Full Application Submission:** Invited applicants submit a detailed proposal, including a detailed project plan, lay summary, budget justification, personnel details, and translational outcomes.

iv. **Scientific and Consumer Assessment:** Full applications undergo in-depth review by ISAC and CRP.

v. **Final Funding Decisions:** Following panel discussions, funding recommendations are made based on assessment scores. Final approvals are determined by the OCRF Board.

vi. **Notification and Funding Agreements:** Applicants are notified of outcomes, and successful projects proceed to contract negotiations and execution of funding agreements.

This process is summarised in the figure below.



5 Funding Information

5.1 General

The OCRF offers grant funding for most aspects of research-related costs. Research proposals may include the salaries of research personnel and other personnel directly or proportionately involved in the project that are not otherwise funded. The costs of consumables, service costs and minor equipment are also included.

Funding is offered from 1 July of the year after application: that is, a successful application submitted in 2025 commence funding from 1 July 2026. This is due to the nature of the grants assessment process and annual fundraising calendar.

Whilst the OCRF aims to fully fund successful research proposals, there is a limit to the funds available for granting each year. The OCRF therefore reserves the right to ask applicants to review and revise their budgets or to offer reduced or part funding of projects. This will be discussed in a clear and timely manner with research teams and the administering institution.

In the event that funding for a research project is offered concomitantly by another funding body (for example, NHMRC or other private foundation), or post-award of funding from the OCRF, the applicant must notify the OCRF immediately. The OCRF retains the right to withdraw funding or to elect to top up the funds from the alternative funding agency rather than awarding the full amount requested for the grant in order to maximize the impact of our grant-making activity in Australia.

5.2 Project costs

While project costs are not capped, budgets must be realistic, clearly justified, and demonstrate value for money. Applicants should be mindful that large funding requests represent a significant proportion of the OCRF's annual research budget and will only be considered in exceptional circumstances. To maximise impact, applicants are strongly encouraged to seek co-funding or in-kind support from other partners throughout the life of the project.

A detailed budget will only be required at the full application stage. At the Expression of Interest stage, applicants need only provide an estimated total funding request.

5.2.1 Salaries

Applicants may apply for the salaries of any research staff they deem appropriate to ensure successful completion of the project. This may include early-, mid- and senior level career researchers, research assistants, research officers, research nurses, postdoctoral fellows, PhD students, and specialist personnel such as bioinformaticians.

Proposals must include salary information inclusive of details of the personnel's current relationship to the Administering Institution, as follows:

i. current employee base salary or wage

ii. full-time equivalent fraction (FTE) to be allocated only to the OCRF-funded project

iii. on-costs applied by the Administering Institution's model up to a maximum of 25%

iv. any other salary-related expenditure required to support individuals to participate fully and effectively in the project.

5.2.2 Minor equipment and maintenance

Expenditure relating to minor equipment must be fully itemised and justified. Expenditure relating to consumables and other maintenance costs can be shown as an aggregate figure for items with individual costs less than or equal to $2000 and must be fully itemised for items with individual costs greater than $2000.

5.2.3 Consumables

Grant funds may be used to cover the cost of consumables that are directly related to the delivery of the project. This includes, but is not limited to reagents, laboratory disposables, assay kits, cell culture materials, and any other perishable or single-use items essential for the research.

5.2.4 Services

Funding may be requested for research-related services critical to project success. These may include sequencing, mass spectrometry, flow cytometry, imaging, animal facility charges, bioinformatics services, and other core facility services, with cost estimates based on established facility rates.

5.2.5 Indirect and overhead costs

Grant funds cannot be used for indirect institutional overhead costs, often referred to as the 'cost of research' or 'research levies', unless discussed with the OCRF Research Director well in advance of submission.

6 Eligibility

6.1 Administering Institution

i. The proposed project must be located, managed, and operated under the auspices of a tertiary institution, hospital or major research institute (MRI) located within Australia or New Zealand.

ii. A single institution must be nominated as the Administering Institution.

iii. The Administering Institution must have in place policies and procedures for the management of public funds, for the management of Intellectual Property, and for the proper conduct of research in relation to ethics and scientific conduct.

iv. The Administering Institution will be provided a copy of the Funding Agreement upon awarding of the grant and must review and agree to perform the proposed project on the terms of that Funding Agreement for funding to be received.

v. The Administering Institution is responsible for maintaining and renewing required insurances and supplying the OCRF with a copy for the duration of the grant.

6.2 Chief and Associate Investigators

i. The Chief Investigators must demonstrate career excellence and a commitment to carry out research projects that aim to have a significant impact on ovarian cancer. Each application must nominate a Lead Chief Investigator (Lead CI) who takes the lead role in the conduct of the research project and is the investigator who takes responsibility for completion and lodgement of the application as well as the preparation of Progress and Final Reports should the grant be awarded.

ii. A Lead CI can nominate additional Chief Investigators on the application. All Chief Investigators must show a significant and material contribution to the project that justifies their appointment (and where relevant, their salary) in their role. A researcher that serves an advisory only function to the project should be nominated as an Associate Investigator rather than a Chief Investigator.

iii. The Lead CI may also nominate Associate Investigators who provide intellectual input into the research and whose participation warrants inclusion of their name on publications. Associate investigators are not able to draw a salary from the grant.

iv. Researchers are encouraged to include consumer representatives as Associate Investigators and to engage them meaningfully throughout the entire research lifecycle.

At the time of application, Chief Investigators must have:

i. A strong and demonstrated track record of research excellence, skills and experience appropriate to Chief Investigator status;

ii. A salary level commensurate with same;

iii. Demonstrated understanding of OCRF's expectations as set out in these Guidelines, and preparedness to sign the proposal (and later, contract) to indicate the same.

The Lead Chief Investigator and minimum of 50% of the nominated Chief Investigators must:

i. **Reside in Australia or New Zealand (or intend to reside in Australia) throughout the funding period.**
ii. **Be an Australian or New Zealand citizen, have resident status or have an appropriate visa to work in Australia or New Zealand for the entire duration of the funding period.**

In addition, the Lead CI must remain the same for the duration of the project funding period, unless discussed and agreed prior.

6.3 Research Type Eligibility

We invite applications from investigators focused on both discovery and translational laboratory-based research, including experimental methods such as (but not limited to) molecular biology, biochemistry, biomolecular analysis, omics studies, development of novel therapeutics including drug repurposing, functional assays, screening platforms and/or *in vivo* approaches.

6.3.1 Exclusions

Proposals involving epidemiology, psychosocial research, palliative care, allied health, health economics, clinical trials or behavioural research are not currently considered to be eligible for OCRF funding.

7 Assessment of Applications

7.1 Assessment Panels

All applications submitted to the OCRF are reviewed through a rigorous and transparent assessment process involving both scientific and consumer panels. Applications are evaluated based on clearly defined criteria, with final funding recommendations made to the OCRF Board.

7.1.1 International Scientific Advisory Committee

The International Scientific Advisory Committee (ISAC) is made up of leading ovarian cancer researchers and clinicians from Australia and around the world. Members are selected to ensure a range of expertise across disciplines relevant to the OCRF's research priorities. ISAC members independently assess each application, and their insights ensure that OCRF-funded research is aligned with international best practice and positioned to deliver meaningful outcomes for people affected by ovarian cancer.

7.1.2 Consumer Representative Panel

The Consumer Representative Panel (CRP) is made up of individuals with lived experience of ovarian cancer, either as patients, survivors, carers, or family members. Their role is to assess the potential impact of the project on the ovarian cancer community and the quality of consumer involvement in each proposal. The CRP is a core part of the OCRF's commitment to embedding the voice of those affected by ovarian cancer into all funding decisions.

Applicants should note that the CRP is not a general public audience. While lay language is essential, members of the CRP are well-informed about the disease and its research landscape. Therefore, applicants are not expected to explain basic clinical or prognostic information. Instead, emphasis should be placed on the project plan, consumer engagement plan, and how the project can improve outcomes for those affected by ovarian cancer.

7.2 Expression of Interest Assessment Criteria

EOIs will be assessed by the International Scientific Advisory Committee (ISAC) and the Consumer Representative Panel (CRP) against the following five equally weighted criteria:

Criteria	Description	Assessors	Weighting
Innovation	Assesses the novelty of the research concept, approach, or direction. This may include the use of emerging or innovative technologies, tools, or methodologies that have the potential to drive significant progress in ovarian cancer research.	ISAC	20%

Criteria	Description	Assessors	Weighting
Quality and scientific feasibility	Evaluates the strength of the scientific rationale, clarity and logic of the research plan, and overall likelihood of successful project delivery. Includes assessment of how the project advances current knowledge in the field.	ISAC	20%
Translational capacity	Assesses the potential for the research to generate meaningful outcomes that can ultimately be translated into clinical practice, or for patient or community benefit.	ISAC	20%
Relevance and potential impact	Evaluates the project's potential to improve outcomes or experiences for people affected by ovarian cancer. This includes the project's alignment with our community's (and therefore OCRF's) priorities.	CRP	20%
Consumer engagement	Assesses the quality and authenticity of proposed consumer involvement throughout the research process. This includes the inclusion of consumers as Investigators and a clear plan for ongoing engagement.	CRP	20%

7.3 Full Application Assessment Criteria

The International Scientific Advisory Committee (ISAC) conducts the initial assessment of full applications. The ISAC's recommendations for funding are then reviewed by our Consumer Representative Panel (CRP), with feedback from both panels compiled and presented to the OCRF Board who are responsible for making the final funding decisions.

7.3.1 International Scientific Advisory Committee Selection Criteria

The ISAC conducts an in-depth evaluation of the scientific merit and feasibility of each full application, based on the following criteria:

Criteria	Description	Weighting
Innovation	Novelty of the research concept, approach, or direction. This may include the use of emerging or innovative technologies, tools, or methodologies that have the potential to drive significant progress in ovarian cancer research.	20%
Quality and outcomes	Scientific rationale, clarity of the research proposal, likelihood of success, potential translational impact, and contribution to current knowledge.	40%

Criteria	Description	Weighting
Research team	Experience and qualification of researchers (including publications, citations, presentations and committee involvement), evidence of collaboration, and success relative to opportunity.	20%
Project management	Feasibility of the project plan, including timelines, budget justification, and capacity to deliver within the proposed timeframe.	20%

*Note: Please ensure that **Section 2A** of the application form clearly outlines the **anticipated outcomes** of your proposed project, as well as **any alternative approaches** that may be considered. The International Scientific Advisory Committee views this as a critical element of a strong application.*

All submissions will be screened by the OCRF Research Team for completeness and compliance with the Guidelines. Incomplete applications, or those missing required documentation at the time of the deadline, will not proceed to assessment. As the number of applications received consistently exceeds the available funding, late submissions or additional documentation cannot be accepted under any circumstances. Lead Chief Investigators are strongly encouraged to submit well in advance of the closing date.

7.3.2 Consumer Representative Panel Selection Criteria

The CRP evaluates applications from a lived experience perspective, focusing on the following equally weighted criteria:

i. **Relevance, Equity and Alignment**
Assesses the alignment of the proposal with OCRF's mission, including the significance of the issue being addressed and its potential to benefit either a broad population or an underserved group with a high burden of illness, is under-studied or has poorer outcomes.

ii. **Translation and Impact**
Evaluates whether the project includes strategies, collaborations, or dissemination plans that enhance the likelihood of translation into further research, clinical practice, or community benefit.

iii. **Consumer Engagement**
Reviews the extent and authenticity of consumer involvement in the design, conduct, and communication of the research. The level of engagement should be appropriate to the stage and type of research being proposed.

7.4 Assessor Conflicts of Interest

To ensure a fair and unbiased assessment process, all members of the International Scientific Advisory Committee (ISAC) and the Consumer Review Panel (CRP) are required to declare any actual, potential, or perceived conflicts of interest prior to receiving applications.

A conflict of interest exists when a panel member has a personal, professional, or financial interest that could improperly influence, or be perceived to influence, their evaluation of an application. This includes, but is not limited to:

i. Current or recent collaboration with any applicant (within the past three years)

ii. Employment at the same institution as an applicant

iii. Personal relationships with any member of the applicant team

iv. Financial interest in a company or product related to the proposed research

v. Any other situation that may compromise objectivity

All assessors are required to submit a formal COI declaration prior to receiving any application materials. If a conflict is identified, the assessor will be excluded from reviewing, scoring, or participating in any discussion relating to the affected application(s). Conflicted members will not be present during discussions related to the relevant proposal.

7.5 Feedback on Applications

The OCRF does not provide feedback on unsuccessful applications by default. However, brief written feedback may be supplied upon request, with the aim of assisting applicants strengthen future submissions.

8 Grant Administration

8.1 Funding Agreement

Upon awarding of a grant, a Funding Agreement will be prepared and issued to the Administering Institution for review and signature. This Funding Agreement will certify that the institution endorses the application, is willing to administer the Research, and has the appropriate facilities and services to be made available for use by the Lead CI. All parties must accept the terms of the Funding Agreement and sign the Agreement before payments are made.

Projects must be conducted as set out in the Funding Agreement.

8.2 Variations to Funding Agreement

Lead CIs can request to extend the duration of the grant for up to 12 months without any additional OCRF funding. Extensions will be reviewed by the International Scientific Advisory Committee for the currency of the research and approval will need to be granted by the Board.

Extensions beyond 12 months will not be approved.

8.3 Reporting requirements

As a not-for-profit organisation, the OCRF is committed to ensuring responsible stewardship of the funds we invest in research. We strongly encourage researchers to maintain open and ongoing communication with the OCRF, particularly if they encounter any challenges, rather than waiting for formal reporting periods.

Successful Lead CIs will be required to submit Progress Reports on an annual basis outlining the progress and achievements made. The OCRF reserves the right to modify the mode and content requested for submission in the annual reports. **Failure to submit reports on time may lead to the suspension of future funding.**

Successful Lead CIs may also be asked to present to the OCRF Board from time to time on their grant progress.

8.4 Media and community engagement

Media and community engagement is a very important aspect of terms of engagement with the OCRF. It supports delivery of our donor promise to community and partners.

Details of media and community related requirements can be found in the OCRF Funding Agreement. This includes acknowledgement of OCRF contribution to the research project across its life cycle.

9 Privacy & Confidentiality

The OCRF values your privacy and takes reasonable steps to protect your personal information (that is, information that identifies or may reasonably be used to identify you). The OCRF is bound by the *Privacy Act 1988* (the Privacy Act) as well as applicable state/territory legislation so your personal information will be handled and protected in accordance with the provisions of this Act.

The OCRF only collects personal information from you that is necessary for it to perform its functions. For these purposes, your information may be shared with trusted third parties and OCRF's service providers. If you choose not to provide certain personal information to the OCRF, we may not be able to process your grant application or communicate with you.

Our *Privacy Policy* tells you what kinds of information we may collect about you, how we usually collect, use and disclose your personal information, how you can complain about a misuse of your personal information and how you can ask for access to it. You can view our *Privacy Policy* by visiting ocrf.com.au/privacy-policy/.

10 Application Process

This section provides further detail on the information to be submitted as part of the application. Please ensure you complete all sections of the application and adhere to any word limits outlined in the application form. Incomplete applications will not be processed.

10.1 Submission

Applicants must create an OCRF Grants Portal account (https://grants.ocrf.com.au/) and apply for a grant via this portal. PDF applications will **not** be accepted. Grant applications will close by **9am AEST** on the closing day, however highly recommended that Lead CIs submit well in advance of the closing date. Signatures can

be uploaded to the portal as image or PDF files; it therefore recommended that all relevant signatures should be sought well before the closing date. An acknowledgment of application receipt window will immediately follow successful grant submission. For any enquiries, please email grants@ocrf.com.au.

10.2 Expression of Interest Application Stage

This section provides an overview of the information that will be requested through the application portal in the EOI Application stage.

SECTION 1: Contact Details

Lead Chief Investigator - Contact	See Guidelines Section 6: Eligibility for details.
Administering Institution – Contact	The contact person responsible for coordinating the Funding Agreement, invoices and annual progress reports alongside the Lead CI.

SECTION 2: Project Proposal

Study Abstract *Max 800 words.*	A concise overview of your project, including the background, preliminary evidence, aims, hypothesis, methodology, and anticipated outcomes. One A4 figure (with multiple panels if needed) may be included and must be legible. The figure legend is not included in the word count and should be attached separately.
Translational Impact *Max 200 words.*	Describe the translational impact of this project, and its ability to improve outcomes for ovarian cancer patients.
Collaboration *Max 200 words.*	Outline any collaborative components of the project, including partnerships with other researchers, institutions, or networks that will strengthen the proposal and enhance impact.

SECTION 3: Project Planning & Management

Investigator Summary List	Please list all investigators involved in the project, including their full name, affiliated institution, and estimated percentage contribution to the project.
Other Funding	Please list any current or prior funding related to the proposed research. Include the funding body, grant amount, and duration. Additionally, indicate any pending applications for funding related to this research, specifying the funding body and expected decision timeline.
Budget	Provide a single estimated total project cost (numerical value only). The estimate should align with guidance provided in Section 5: Funding Information and reflect realistic expectations for project delivery. A detailed budget will be requested at the full application stage.

SECTION 5: Consumer Review

Consumer Engagement *300 words*	Indicate how consumers have been involved in the development and planning of this research proposal. Describe the nature of their involvement to date and outline how meaningful engagement with consumers will be maintained throughout the project, appropriate to the stage and type of research.

SECTION 6: Certification

Lead Chief Investigators must confirm that all investigators have agreed to participate, the project is institutionally supported and compliant with relevant standards, and certify the accuracy of the information provided and agreement to abide by the OCRF Research Grant Guidelines and conditions. Certification by the Administering Institution and the Department Head is required at the Full Application stage only.

10.3 Full Application Stage

This section provides an overview of the information that will be requested through the application portal in the Full Application stage.

SECTION 1: Contact Details

As per EOI Stage.

SECTION 2: Project Proposal

Synopsis	Should include background, aim(s), methodology, impact and significance.
Proposed Study	Background information, preliminary data, aim(s), methodology, and an overview of the research strategy and plans for the duration of the research project. Please be as concise as possible. Relevant critical reference should be included. Please attach any relevant images/figures in this section as a single pdf file and clearly label them with figure legends.
OCRF Research Priorities & Relevance	Outline the overall direction, contribution, and significance/relevance of the research project to ovarian cancer research and how the project aligns with the OCRF Research Priorities.
Translational Impact	Discussion of the potential for translational impact of the research and how the outcomes of the research project may in the short, medium and/or long-term impact on ovarian cancer in Australia and New Zealand.

SECTION 3: Project Planning & Management

Milestones & Deliverables	Milestones should outline significant events or outcomes that you aim to reach throughout the research period. Deliverables are of a short-term nature and

	there should be measurable goals throughout each reporting period. These will be used to determine the progress and success of your research project.
Project Timelines	Timetable the major activities to be conducted in each year including the expected timeframes. This should align with your research strategy/plans as outlined in the proposed study section.
Budget & Justification	Provide a detailed budget and a clear justification for each salary (if requested) and any other research support. Titles and salary figures must be commensurate to the position and involvement of the staff member. Costs must fit within the guidelines provide in Section 5: Funding Information.
Other Funding	All funding secured from additional sources (host institution, university, government agencies, other not for profit organisations, etc.) must be reported in this section and itemised. This allows the OCRF to assess and articulate the value proposition of its funding to a range of supporters and the community.
Ethics	Lead CIs need to complete this section acknowledging whether ethics approval needs to be, has been sought, or has been, achieved. Successful Lead CIs will need to provide final ethics clearance(s) to the OCRF before project commencement and the release of funding.

SECTION 4: Research Team

Investigator – Contact Details	Please ensure this is completed for all Investigator/s. Lead CI details do not need to be provided again as they were completed in Section 1.
Citizenship & Visa Status	As stated in Section 5, the Lead CI and at least 50% of the nominated Chief Investigators must be an Australian or New Zealand citizen, an Australian or New Zealand Permanent Resident or hold a relevant visa to work in Australia or New Zealand. Lead CIs who have not yet been granted a relevant visa status may apply provided that such status has been sought. Evidence must be provided with the application.
Participation in Project	Outline the percentage of time each Chief Investigator will be contributing to the research project and include a brief overview of their role on the project. Ensure this aligns with any CI salaries included in your budget.

Research & Professional Experience	Include a brief biography which will be utilised in any marketing and communication material and the website for the OCRF should the application be successful. Provide a career chronology including any awards and honours and any current memberships on advisory committees. Also include only the top 5 publications over the past 5 years, and any representative earlier publications pertinent to this application. Please include citations where possible.

SECTION 5: Consumer Review

Lay Description	Lead CIs must include a brief description of the research project **IN LAY TERMS**. It is essential that care is taken to provide a non-scientific summary in simple, easy-to-understand, non-technical language, which explains the rationale, research objectives and the relevance of the project to OCRF's purpose and ovarian cancer research. Lead CIs are encouraged to work with their institution's communications staff and consumers on this section. If successful, the lay description may be used in the production of a range of printed, digital and other communication materials and channels, promoting research funded by the OCRF. Be mindful to spend a majority of the word limit on describing your research as opposed to outlining the ovarian cancer landscape.
Relevance, Equity and Alignment	Highlight ways in which the potential research outcomes could benefit an ovarian cancer population or group that has a high burden of illness, has been under-studied or has poorer outcomes. Alternatively, please describe how the research outcomes could provide widespread benefit to the ovarian cancer community.
Translation and Impact	Describe how the research outcomes will be clinically translated to positively impact ovarian cancer incidence, prevention, diagnosis or management. Response should include details of these impacts in the short, medium, and long term.
Consumer Engagement	Indicate whether consumers have been involved in the development and planning of this research proposal. Describe how consumers have been engaged and ways in which this will continue throughout the duration of the project, consummate with the stage and type of research.

SECTION 6: Certification

All Chief Investigators must certify that all the details given in the application are correct and that they agree to carry out the project according to the conditions determined by the OCRF.

The Lead CI must ensure that the Administering Institution and the Head of the relevant Department within the Administering Institution which will host the project have approved the application and authorised the Lead CI to submit the application by completing the relevant certification section. Incomplete certifications will not be considered.